• Do not administer ABRAXANE therapy to patients who have baseline
neutrophil counts of less than 1500 cells/mm3. In order to monitor
the occurrence of bone marrow suppression, primarily neutropenia,
which may be severe and result in infection, it is recommended that
frequent peripheral blood cell counts be performed on all patients
receiving ABRAXANE

• Note: An albumin form of paclitaxel may substantially affect a drug’sfunctional properties relative to those of drug in solution. DO NOTSUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS

ABRAXANE is indicated for the first-line
treatment of patients with metastatic
adenocarcinoma of the pancreas (MPAC),
in combination with gemcitabine.

ABRAXANE is indicated for the first-line
treatment of locally advanced or metastatic
non–small cell lung cancer (NSCLC),
in combination with carboplatin, in patients
who are not candidates for curative surgery
or radiation therapy.

ABRAXANE is indicated for the treatment
of breast cancer after failure of combination
chemotherapy for metastatic disease or relapse
within 6 months of adjuvant chemotherapy.

Prior therapy should have included an
anthracycline unless clinically contraindicated.

Important Safety Information
ignited we stand with

Please see additional Important Safety Information and Brief Summary for ABRAXANE, including Boxed WARNING,
on following pages.